KING PHARMACEUTICALS INC
Healthcare · Pharmaceutical Preparations · TN · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annualNo structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).
Signs
● 1 severe● 0 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 17, 2005
- NT 10-Qmissed a reporting deadline ↗Nov 10, 2004
- NT 10-Qmissed a reporting deadline ↗May 15, 2003
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2003
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Recruitingreadout ~2025-05-31Investigating the Efficacy of Combining Virtual Reality-Based Mirror Therapy (VRMT) and Transcranial Direct Current Stimulation (tDCS) to Improve Upper Limb Recovery in Patients with Stroke
- Phase 4Active Not Recruitingreadout ~2025-06-30Assessing the Effects of Resin Infiltration and Resin Modified Glass Ionomer on the Color Changes of White Spot Lesions in a Clinical and Laboratory Setting
- Phase 4Recruitingreadout ~2025-06-30Effect of Silver Diamine Fluoride Application on Oral Microbiome of Healthy Pediatric Patient
- Phase 4Not Yet Recruitingreadout ~2025-08-15The Prolonging Effect of Dexmedetomidine on Spinal Anesthesia Through Different Routes if Administrations
- Phase 3Recruitingreadout ~2025-10-30Art-Based Pain Assessment Tool in Patients With Temporomandibular Joint Disorders
- Phase 4Recruitingreadout ~2025-12-31Zinc Oxide VS MEBO
- Phase 4Recruitingreadout ~2026-01-01Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome
- EARLY_Phase 1Active Not Recruitingreadout ~2026-03Comparing Microneedling and Injectable Platelet Rich Fibrin to Hyaluronic Acid In Papilla Reconstruction
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Bailey Jeffrey AllenOfficer — Chief Commercial Officer | Jan 31, 2011 | D | 40,000 | — |
| Brouillette Frederick JrOfficer — Corporate Compliance Officer | Jan 31, 2011 | U | 77,543 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Director / officer changeFeb 22, 2011
- Delisting / listing-standard noticeFeb 8, 2011
- Terminated a material agreement · Debt acceleration / triggering event · Change in control · Director / officer change · Other material eventFeb 4, 2011
- Director / officer changeJan 24, 2011
- Director / officer changeOct 15, 2010
- Entered a material agreement · Other material eventOct 12, 2010
- Results of operationsAug 9, 2010
- Entered a material agreementJul 29, 2010
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- NO ACTAUTO-GENERATED PAPER DOCUMENTMar 11, 2011
- NO ACTAUTO-GENERATED PAPER DOCUMENTMar 11, 2011
- 4FORM 4 SUBMISSIONMar 1, 2011
- 4FORM 4 SUBMISSIONMar 1, 2011
- 4FORM 4 SUBMISSIONMar 1, 2011
- 4FORM 4 SUBMISSIONMar 1, 2011
- 4FORM 4 SUBMISSIONMar 1, 2011
- 4FORM 4 SUBMISSIONMar 1, 2011
- 4FORM 4 SUBMISSIONMar 1, 2011
- 4FORM 4 SUBMISSIONMar 1, 2011
- 4FORM 4 SUBMISSIONMar 1, 2011
- 15-12BFORM 15Mar 1, 2011
- SC TO-I/AAMENDMENT NO. 1 TO SCHEDULE TOMar 1, 2011
- EFFECTFeb 23, 2011
- EFFECTFeb 23, 2011
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.